Carlyle's portfolio companies, Sequent Scientific and Viyash Life Sciences, have received National Company Law Tribunal approval for their planned Rs 8,000 crore merger. This strategic combination aims to leverage back-end synergies between Sequent's animal health business and Viyash's human health drug manufacturing operations. Hari Babu Bodepudi, Viyash's founder, will lead the combined entity as CEO.